Biohaven (BHVN) announced that it has initiated a global Phase 2/3 study of the first-in-clinic, orally-administered, brain-penetrant, and highly selective TYK2/JAK1 inhibitor, BHV-8000, for the treatment of early Parkinson’s disease. The trial will enroll 550 patients at approximately 185 sites across 13 countries including the United States, Canada, and 11 European nations.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHVN:
- Optimistic Buy Rating for Biohaven Ltd. Amid Promising Pipeline and Regulatory Challenges
- Biohaven Ltd.: Promising Pipeline and Undervaluation Justify Buy Rating
- Biohaven announces ‘positive’ TRAP degrader data
- Biohaven provides oncology program update
- RBC downgrades Biohaven to Sector Perform on regulatory risk